Table 3. Summary of the main characteristics of the cohort.
| GSVL | Year sampled | Country sampled | Transmission mode | Sex | Age at infection | Ethnicity | Subtype | Sequence length (bp) |
|---|---|---|---|---|---|---|---|---|
| Min.: 2.000 | Min.: 1985 | BE: 52 | HEAM/TRANSF: 3 | Female: 295 | Min.: 17 | Black: 36 | B: 1,581 | Min.: 601 |
| 1st Qu.: 4.167 | 1st Qu.: 2004 | CH: 1,005 | HET: 475 | Male: 1,733 | 1st Qu.: 29 | White: 421 | A1: 113 | 1st Qu.: 7,669 |
| Median: 4.675 | Median: 2007 | FR: 378 | HET/IDU: 44 | Median: 35 | Other/Unknown: 1,571 | 02_AG: 107 | Median: 9,018 | |
| Mean: 4.573 | Mean: 2006 | NL: 480 | IDU: 90 | Mean: 36 | 01_AE: 68 | Mean: 8,168 | ||
| 3rd Qu.: 5.066 | 3rd Qu.: 2009 | UK: 113 | MSM: 1343 | 3rd Qu.: 42 | C: 41 | 3rd Qu.: 9,068 | ||
| Max.: 7.002 | Max.: 2015 | MSM/IDU: 1 | Max.: 78 | D: 25 | Max.: 9,639 | |||
| Other/Unknown: 72 | Unknown: 445 | (Other): 93 |
BE, Belgium; CH, Switzerland; FR, France; GSVL, gold standard viral load; HEAM/TRANSF, haemophiliac or blood transfusion; HET, heterosexual; IDU, injecting drug user; MSM, men having sex with men; NL, the Netherlands; UK, United Kingdom.